Pacira BioSciences, Inc.
PCRX · XNASCIK 1396814fmd_179ANMYGRXJSJTDG2YY8TCG0T7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 276 | 287 | 337 | 421 | 430 | 542 | 667 | 675 | 701 | 726 |
| Cost of revenue | 110 | 88 | 87 | 107 | 117 | 140 | 199 | 185 | 170 | 150 |
| Gross profit | 166 | 199 | 250 | 314 | 312 | 401 | 468 | 490 | 531 | 577 |
| Realized investment gains (losses) | 0 | 0 | 1 | (4) | 2 | (3) | – | – | – | – |
| Research and development | 46 | 57 | 56 | 72 | 59 | 56 | 85 | 76 | 82 | 117 |
| Selling, general and administrative | 153 | 161 | 177 | 201 | 194 | 199 | 255 | 269 | 294 | 369 |
| Total operating expenses | 308 | 312 | 321 | 411 | – | – | – | – | – | – |
| Operating income | (32) | (25) | 16 | 10 | 46 | 90 | 60 | 88 | (73) | 19 |
| Interest expense | 7 | 18 | 22 | 24 | 26 | 32 | 40 | 20 | 17 | 17 |
| Interest and investment income | 1 | 4 | 6 | 7 | 5 | 1 | 5 | 11 | 20 | 23 |
| Other non-operating income (expense) | (6) | (18) | (16) | (21) | (26) | (34) | (47) | (26) | 10 | (2) |
| Income before taxes | (38) | (42) | (0) | (11) | 20 | 56 | 13 | 62 | (63) | 17 |
| Income tax expense | 0 | 0 | 0 | 0 | (125) | 14 | (3) | 20 | 36 | 10 |
| Net income from continuing operations | (38) | (43) | (0) | (11) | 146 | 42 | 16 | 42 | (100) | 7 |
| Net income | (38) | (43) | (0) | (11) | 146 | 42 | 16 | 42 | (100) | 7 |